Please assess the completion status of the following clinical trial:

Trial Title: Role of Dexamethasone in the Conservative Treatment of Chronic Subdural Hematoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years and older~* evidence of subacute or chronic supratentorial subdural hematoma by CT (computerized tomography) scan or MRI (magnetic resonance imaging)~* classified between 0 and 2 using the Markwalder grading scale~Exclusion Criteria:~* contraindications or intolerance to corticosteroid therapy~* patients already undergoing steroid treatment for any other indication~* previous neurological surgery up to one year prior to being considered for the study~* concomitant cerebral pathology of neoplastic or presumed infectious origin~* anticoagulant therapy that could not be stopped for 6 months~* refusal to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: EXPERIMENTAL): Participants allocated to the treatment group received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
- Control (Type: PLACEBO_COMPARATOR): Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).